 |
- Bachem began in 1971, when Peter Grogg founded Bachem Feinchemikalien AG with two employees in Liestal near Basel.
- In 1977, Bachem moved with eight employees to near-by Bubendorf, and, in 1978, it manufactured, for the first time, peptides for use in medicine under cGMP guidelines. Between 1981 and 1991 Bachem tripled its production capacity and built an administration building, while the number of employees grew to 150.
- In 1995, facilities were further expanded including the quality control department to a total of 168'000 sq. ft. (15'600 m2), and employees totalled 190.
- Expansion into markets outside Europe began with the establishment of Bachem Bioscience, Inc. in Philadelphia, USA in 1987. To strengthen its presence in Europe, Bachem opened sales and marketing centers in Germany in 1988 and in France in 1993. In 1996 it acquired its largest competitor, Bachem, Inc., together with its subsidiaries in Germany and the United Kingdom. In June 1998, following a very successful IPO, Bachem's shares began to be publicly traded on the Swiss Stock Exchange.
- The Group had total sales of CHF 96 million in 1998 and a headcount of 331 employees. In 1999 a new administration building, and in 2000 a further production facility were opened at the Bubendorf site.
- With the acquisition of the San Carlos, California based Peninsula Laboratories, Inc. and its affiliate Peninsula Laboratories Ltd., United Kingdom in December 1999, Bachem extended its strong position in therapeutically active peptides into immunology, a domain with strong future promise.
- In August 2000, Peninsula Laboratories Europe Ltd. and Bachem (UK) Ltd. merged together to a single Bachem group affiliated company in the United Kingdom.
- The acquisition of Sochinaz SA, a Swiss-based specialized manufacturer of active pharmaceutical ingredients in 2001, has strengthened Bachem's expertise and has once again expanded its manufacturing capabilities. The headcount of the Group has grown to 500 employees.
- Reorganization of distribution in Germany and France as a result of the positive experiences gained with the realignment of the sales and marketing organization in the USA. The subsidiary in France has been closed at the end of 2002. The subsidiary in Germany has been relocated from Heidelberg to Weil am Rhein, was renamed to Bachem Distribution Services GmbH and is now responsible for all customers in the European Union.
- In 2003, a holding structure was introduced to align the factual organisation of the company with an appropriate legal structure and to support management structure adjustments, given by continued company growth requirements.
- In 2006, the Bachem Group had a total sales of CHF 172 million and a headcount of 645.
- In 2007, Bachem aquired the Clinalfa® brand for Bachem's ready-to-use clinical trial materials and related services.
| |
|
|
